Ask Schedule call for Mild Cognitive Impairment Market Size, Share, Trends 2032

SCHEDULE CALL

Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson’s Disease Dementia, Alzheimer’s Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032

Mild Cognitive Impairment Market

Mild cognitive impairment market size is projected to be worth USD 2.96 billion by 2030, registering a CAGR of 5.30% during the forecast period 2022 - 2030

$2.96 Billion

Market Size

5.30%

CAGR

North America

Dominating Region

2022 - 2030

Forecast Period

Segmentation

Key Players

Companies Profiled • Pfizer Inc. (US) • Hoffman La Roche Ltd (Switzerland) • Novartis AG (Switzerland) • Accord UK Ltd (UK) • Reddy’s laboratories Ltd (India) • Hikma Pharmaceuticals PLC (UK) • Sun Pharmaceuticals ltd (India) • Johnson & Johnson Services Inc. (US) • Teva Pharmaceutical Industries Ltd. (Israel)

Drivers

No. of Pages: 151

Report Code : MRFR/HC/9432-CR

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

SCHEDULE CALL

Mild Cognitive Impairment Market

CLIENTS TESTIMONIALS